Protagonist Therapeutics (PTGX) Long-Term Investments (2016 - 2026)

Protagonist Therapeutics (PTGX) has 9 years of Long-Term Investments data on file, last reported at $72.5 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 41.26% year-over-year to $72.5 million; the trailing twelve-month figure through Mar 2026 stood at $72.5 million (down 41.26% YoY), and the FY2025 full-year result was $78.6 million, down 43.98% from the prior year.
• Long-Term Investments declined to $72.5 million in Q1 2026, from $78.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $140.3 million in Q4 2024 to a low of $2.0 million in Q3 2023.
• A 4-year average of $85.4 million and a median of $102.5 million in 2025 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments surged 5673.3% in 2024 and slumped 43.98% in 2025, its largest moves.
• Tracing PTGX's Long-Term Investments over 4 years: stood at $2.0 million in 2023, then soared by 6968.01% to $140.3 million in 2024, then tumbled by 43.98% to $78.6 million in 2025, then dropped by 7.7% to $72.5 million in 2026.
• Business Quant data shows PTGX's Long-Term Investments at $72.5 million in Q1 2026, $78.6 million in Q4 2025, and $102.7 million in Q3 2025.